Samsung Biologics Co.,Ltd.

KSE 207940.KS

Samsung Biologics Co.,Ltd. Gross Profit Margin for the year ending December 31, 2023: 48.57%

Samsung Biologics Co.,Ltd. Gross Profit Margin is 48.57% for the year ending December 31, 2023, a -0.73% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Samsung Biologics Co.,Ltd. Gross Profit Margin for the year ending December 31, 2022 was 48.93%, a 5.61% change year over year.
Samsung Biologics Co.,Ltd. Gross Profit Margin for the year ending December 31, 2021 was 46.33%, a 29.70% change year over year.
Samsung Biologics Co.,Ltd. Gross Profit Margin for the year ending December 31, 2020 was 35.72%, a 30.53% change year over year.
Samsung Biologics Co.,Ltd. Gross Profit Margin for the year ending December 31, 2019 was 27.37%, a 1.02% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

KSE: 207940.KS

Samsung Biologics Co.,Ltd.

CEO	Mr. John Chongbo Rim
IPO Date	Nov. 11, 2016
Location	South Korea
Headquarters	300, Songdo Bio-daero
Employees	4,523
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Key trends

Past 5 years